Novo Nordisk (CPSE:NOVO B) Is Up 9.0% After FDA Clears First Oral Wegovy Pill [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
for chronic weight management and cardiovascular risk reduction, with trial data showing weight loss broadly comparable to the injectable 2.4 mg dose. The needle-free, lower-priced pill, positioned for broad distribution through pharmacies and telehealth channels, could materially widen access to obesity treatment and reinforce semaglutide as a cornerstone therapy across multiple metabolic and cardiovascular indications. Next, we'll examine how being first to market with an oral GLP-1 pill could reshape Novo Nordisk's obesity-led investment narrative. This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality To own Novo Nordisk, you need to believe obesity and cardiometabolic care remain a long multi decade growth theme and that Novo can defend Wegovy and Ozempic margins even as access broadens and pricing pressure builds. The Wegovy pill approval looks like the key near term catalyst because it could accelerate U.S. volum
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Health care will get more expensive for some in 2026 — and cheaper for others [MSNBC.com]MSNBC.com
- U.S. regulators approve Wegovy pill for weight loss [Los Angeles Times (CA)]Los Angeles Times
- Novo, Lilly race to cement lead in India's obesity drug market, Reuters says [Yahoo! Finance]Yahoo! Finance
- Health care will get more expensive for some in 2026 – and cheaper for others [MSNBC.com]MSNBC.com
- Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website